Drug Profile
MB 106
Alternative Names: CD20-targeted CAR T cell therapy; MB-106; MB-106 CD20 CAR - Mustang BioLatest Information Update: 14 Dec 2023
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Fred Hutchinson Cancer Research Center; Mustang Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 11 Dec 2023 Efficacy and adverse event data from a phase I/II trial in B-cell non-Hodgkin lymphoma and Chronic lymphocytic leukemia released by Mustang Bio
- 09 Dec 2023 Efficacy and adverse event data from a phase I/II trial in Non-Hodgkin lymphoma and Chronic lymphocytic leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 14 Nov 2023 Mustang Bio plans an end-of-phase-I meeting with US FDA in the first quarter of 2024